Doing Things Differently: Reliable Supply, Real Impact.

How YARAL Pharma’s Consistent Delivery Supports its Customers, Healthcare Partners, and Patients

In today’s healthcare environment, consistent access to medicines is more important than ever. Drug shortages, supply disruptions, and backorders continue to create challenges across the pharmaceutical supply chain, affecting distributors, pharmacies, healthcare providers, and ultimately patients. In this landscape, reliable supply is more than a logistics metric—it is essential to ensuring patients receive the medicines they need.

At YARAL Pharma, maintaining dependable access to high-quality medicines is central to the company’s philosophy of Doing Things Differently.

Delivering medicine to a patient involves far more than manufacturing. From sourcing active pharmaceutical ingredients to quality assurance, global transportation, and distribution, every step must work together seamlessly before a product reaches the pharmacy shelf.

“If the drug isn’t on the shelf when the patient needs it, that’s a problem,” says YARAL Pharma CEO Stephen Beckman. “There are many layers involved in getting medicines from manufacturing to the pharmacy, and every one of those steps matters.”

A Disciplined Approach to Generics

Generics account for more than 90% of prescriptions dispensed in the United States, making continuity of supply a critical component of the healthcare system. These dynamics highlight the importance of manufacturers that prioritize reliability and long-term partnerships.

At YARAL Pharma, that reliability begins with a disciplined approach to portfolio development and supply chain management.

“Doing Things Differently means building a company around discipline and trust,” Beckman explains. “The generics market has often rewarded speed and scale, but we focus on sustainability. We don’t want 100 products—we want the right products, delivered the right way.”

That strategy has helped YARAL Pharma consistently achieve approximately 95% on-time, shipping to customers^*, a key benchmark in pharmaceutical supply chains that reflects how reliably manufacturers deliver product to their customers.

Partnerships That Strengthen the Supply Chain

Maintaining consistent supply requires close coordination across the healthcare ecosystem. YARAL Pharma works closely with a top global healthcare services organization that provides third-party logistics, operational support, and customer service capabilities. These partnerships help ensure customers – including wholesalers, distributors, and pharmacies – receive product on schedule and can plan with confidence.

“Reliable supply removes friction across the system,” Beckman notes. “When our customers know they can count on us, it helps them focus on serving patients.”

For YARAL Pharma, reliability is about more than operational success—it is about supporting the entire healthcare ecosystem. “Reliable supply isn’t just a metric,” Beckman says. “It’s a responsibility.”

At YARAL Pharma, that commitment continues to guide the company’s mission to Do Things Differently,supporting customers, healthcare partners and ensuring patients have dependable access to the medicines they rely on.

Stay tuned as we continue to share stories of the people—and partnerships—that redefine what’s possible when you Do Things Differently.

*Source: Supply chain performance data 2025

 YPM-1540-EN-v1

YARAL Pharma Reinforces Its Commitment to Doing Things Differently

A guiding philosophy shaping how the company operates, partners, and grows in the U.S. generics market

Parsippany, NJ – May 8, 2026 – YARAL Pharma Inc. (YARAL Pharma), the rapidly growing U.S. generics subsidiary of IBSA (Institut Biochimique SA), a multinational pharmaceutical company headquartered in Lugano, Switzerland, today reinforced its commitment to Doing Things Differently  – a guiding philosophy shaping the company’s initiatives in 2026 and informing how it defines success in the U.S. generics market. Throughout the year, YARAL Pharma will integrate the Doing Things Differently tagline across its corporate branding, marketing, and sales efforts.

Founded in 2022, YARAL Pharma entered the U.S. market with a deliberate strategy to challenge the traditional high-volume, commoditized generics model. Instead, the company has focused on “winning with the right marbles,” prioritizing differentiated, complex, and niche products that create sustainable value, through right pricing, continuity of supply and service levels. This philosophy serves as the foundation for YARAL Pharma’s Doing Things Differently approach.

“At YARAL, we are redefining what it means to be a generics company,” said Stephen Beckman, CEO, YARAL Pharma. “Doing Things Differently reflects our belief that patients, pharmacists, and healthcare partners deserve more consistency, more innovation, and more accountability. That commitment shows up in more ways than just access to affordable medicine and shows in the way we operate, partner, and grow—every day.”

Doing Things Differently serves as a unifying platform across YARAL Pharma’s communications and strategic initiatives reinforcing the company’s focus on:

• Raising the bar for quality and supply reliability within the generics space
• Investing in customer-first service and responsiveness
• Building strong, transparent relationships with pharmacists, wholesalers, and healthcare systems
• Driving meaningful innovation in how generics are delivered to the market
• Operating with agility and accountability as the company continues its rapid growth trajectory

To learn more about YARAL Pharma’s commitment to Doing Things Differently, visit:
www.yaralpharma.com.  

About YARAL Pharma
YARAL Pharma Inc. (Parsippany, N.J.) is the U.S. generics subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. By focusing on people and innovating the ways they’re cared for, YARAL Pharma is proud to offer the same values and expertise of its parent company to the U.S. market. Dedicated to ensuring access to affordable authorized generics (AGs) and complex generic medicines that enhance healthcare outcomes, YARAL Pharma offers its customers high-quality products across a range of therapeutic areas, continuity of supply, and a commitment to exceptional customer service. For more information, visit www.yaralpharma.com or contact info@yaralpharma.com or 866-218-9009.

About IBSA
IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA celebrated the 40^th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,500 personnel worldwide. IBSA’s growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people.

Doing Things Differently: YARAL Pharma Brings Generics Direct to Patients Through UpScriptHealth

At YARAL Pharma, Doing Things Differently means challenging traditional assumptions about how generic medicines are delivered and accessed. One example of this approach is the Company’s collaboration with UpScriptHealth, a leading direct-to-patient telehealth company — making YARAL Pharma’s products the only generic pain medication available through UpScriptHealth.

Telehealth has become an increasingly important part of the healthcare landscape, offering patients a convenient way to connect with licensed clinicians and access treatment. YARAL recognized an opportunity to extend the reach of high-quality, affordable generic medicines into this growing digital care model, giving patients more options when seeking timely care.

Through UpScriptHealth’s online platform, patients can consult with licensed healthcare providers who assess eligibility and, when appropriate, prescribe YARAL’s prescription products. This model creates an efficient and secure pathway to care while supporting continuity of supply and maintaining the integrity of the prescription process through participating pharmacies.

“Partnering with UpScriptHealth allows us to expand access and convenience for patients while reinforcing YARAL Pharma’s focus on continuity of supply, quality, and customer service,” said Stephen Beckman, Chief Executive Officer, YARAL Pharma. “This collaboration helps us reach patients who may benefit from our products and reflects our goal of redefining what success looks like in the U.S. generics market.”

Exploring new access models reflects YARAL’s broader commitment to innovation in generics—embracing new channels that align with evolving patient expectations while staying grounded in quality, reliability, and service. It also complements the Company’s long-standing focus on supporting pharmacists by thoughtfully integrating generics into emerging care pathways that extend beyond traditional settings.

As the U.S. generics market continues to evolve, YARAL remains focused on partnerships that expand access, improve affordability, and deliver meaningful solutions for patients and healthcare professionals alike.

Stay tuned as we continue to share stories of the people—and partnerships—that redefine what’s possible when you Do Things Differently.

PM# YPM-1434

YARAL Pharma is proud to sponsor Charles Hoopes in the Back Seat Drivers racing series for the 2025 season.

Charles’s path into professional drag racing was anything but traditional. Years after stepping away from the sport, he reignited his passion—restoring an aging dragster, rebuilding it piece by piece, and transforming it into a safe, high-performance vehicle. Along the way, he applied a business mindset, meticulous attention to detail, and a fierce commitment to safety.

“Charles’s grit and determination align perfectly with our values at YARAL Pharma. We believe in doing things differently—whether it’s how we approach business, support our partners, or serve our patients. Charles embodies this mindset through his unconventional journey into racing. We’re proud to support him and the Back Seat Drivers series as a reflection of our shared philosophy.” –Stephen Beckman, CEO of YARAL Pharma

Q&A with Charles Hoopes

Q: How did you get into racing?
A: “It’s all my brother’s fault,” Charles laughs. As a kid, he tagged along to Maple Grove Raceway and was instantly hooked by the sound, speed, and excitement. “One of my first memories is actually getting hurt at the track—ran headfirst into some rocks chasing a fire burnout. But Maple Grove took great care of me. That experience just fueled my love for the sport.”

Q: What brought you back to racing after all those years away?
A: “My kids surprised me with a ride-along in a two-seat dragster. After that one pass, I was hooked all over again. I partnered with a friend who had a car sitting in a garage, and we brought it back to life—rebuilt it completely from the ground up.”

Q: How do you approach racing differently?
A: “We treat it like a business. Testing, logging data, improving one piece at a time. Safety is everything—I wouldn’t get in the car if I didn’t trust it. We don’t cut corners, and we don’t guess. We think it through and do it right.”

Q: Racing looks intense—how do you manage the physical toll?
A: “It’s demanding, for sure. You’re climbing in and out of the car, constantly bending, kneeling, checking tire pressure. I played hockey for decades, so I’ve learned how to manage acute pain. You do what you have to do.”

Q: What does ‘Doing Things Differently’ mean to you?
A: “To me, it’s about problem-solving. Whether I’m restoring a historic building or rebuilding a race car, I’m always thinking creatively. You don’t take shortcuts—you look for better ways to get the job done.”

Stay tuned as we continue to share stories of people—and partnerships—that redefine what’s possible when you Do Things Differently.

Learn more, about our sponsorship with Charles.